• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长链非编码 RNA MALAT1 通过调节 miR-200a-3p/程序性死亡配体 1 轴促进非小细胞肺癌进展。

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.

机构信息

1 Department of Pulmonary and Critical Care Medicine, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.

2 Department of Pathology, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.

出版信息

Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419859699. doi: 10.1177/2058738419859699.

DOI:10.1177/2058738419859699
PMID:31240979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6595645/
Abstract

This study was to investigate the expression correlation between long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNA MALAT1), miR-200a-3p and programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), and their roles in NSCLC. Real-time polymerase chain reaction (PCR) was performed to detect the expressions of MALAT1, miR-200a-3p and PD-L1 in NSCLC tissues and cells for the correlation analysis. The starBase and Targetscan databases were used to predict the binding sites between MALAT1 and miR-200a-3p, and miR-200a-3p and PD-L1, respectively. The targeting relationship between MALAT1 and miR-200a-3p, and miR-200a-3p and PD-L1 were further verified by real-time PCR and dual luciferase reporter gene assay. Cell proliferation was monitored by CCK8 and colony formation assays. The apoptosis was detected using flow cytometry. Wound healing assay and transwell assay were conducted to determine cell migration and invasion. In this study, we demonstrated that in NSCLC tissues, the expression level of MALAT1 was negatively correlated with that of miR-200a-3p, while positively correlated with PD-L1. Besides, MALAT1 promoted proliferation, mobility, migration, and invasion of NSCLC cells via sponging miR-200a-3p. PD-L1 was validated as a target of miR-200a-3p, and indirectly modulated by MALAT1. In conclusion, LncRNA MALAT1 facilitates the progression of NSCLC by modulating miR-200a-3p/PDL1 axis.

摘要

本研究旨在探讨长链非编码 RNA 转移相关肺腺癌转录本 1(lncRNA MALAT1)、miR-200a-3p 与程序性死亡配体 1(PD-L1)在非小细胞肺癌(NSCLC)中的表达相关性及其在 NSCLC 中的作用。采用实时聚合酶链反应(PCR)检测 NSCLC 组织和细胞中 MALAT1、miR-200a-3p 和 PD-L1 的表达情况,并进行相关性分析。利用 starBase 和 Targetscan 数据库分别预测 MALAT1 与 miR-200a-3p、miR-200a-3p 与 PD-L1 的结合位点。进一步通过实时 PCR 和双荧光素酶报告基因检测验证 MALAT1 与 miR-200a-3p、miR-200a-3p 与 PD-L1 的靶向关系。采用 CCK8 和集落形成实验检测细胞增殖,流式细胞术检测细胞凋亡,划痕愈合实验和 Transwell 实验检测细胞迁移和侵袭。本研究表明,在 NSCLC 组织中,MALAT1 的表达水平与 miR-200a-3p 呈负相关,与 PD-L1 呈正相关。此外,MALAT1 通过海绵吸附 miR-200a-3p 促进 NSCLC 细胞的增殖、迁移和侵袭。PD-L1 被验证为 miR-200a-3p 的靶基因,并且可被 MALAT1 间接调控。总之,长链非编码 RNA MALAT1 通过调节 miR-200a-3p/PDL1 轴促进 NSCLC 的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/7978259d3d99/10.1177_2058738419859699-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/fbad447ebbd6/10.1177_2058738419859699-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/db91c4377862/10.1177_2058738419859699-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/22225047f008/10.1177_2058738419859699-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/705044d6896a/10.1177_2058738419859699-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/7978259d3d99/10.1177_2058738419859699-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/fbad447ebbd6/10.1177_2058738419859699-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/db91c4377862/10.1177_2058738419859699-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/22225047f008/10.1177_2058738419859699-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/705044d6896a/10.1177_2058738419859699-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58d7/6595645/7978259d3d99/10.1177_2058738419859699-fig5.jpg

相似文献

1
LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.长链非编码 RNA MALAT1 通过调节 miR-200a-3p/程序性死亡配体 1 轴促进非小细胞肺癌进展。
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419859699. doi: 10.1177/2058738419859699.
2
LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.长链非编码RNA MALAT1通过靶向miR-206并激活Akt/mTOR信号通路促进非小细胞肺癌的迁移和侵袭。
Anticancer Drugs. 2018 Sep;29(8):725-735. doi: 10.1097/CAD.0000000000000650.
3
Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer.长链非编码 RNA MALAT1 通过 miR-374b-5p/SRSF7 轴调控非小细胞肺癌的增殖、凋亡、迁移和侵袭。
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1853-1862. doi: 10.26355/eurrev_202002_20363.
4
LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.长链非编码 RNA SNHG1 通过 miR-361-3p/FRAT1 轴影响非小细胞肺癌细胞的增殖、迁移、侵袭和凋亡。
Thorac Cancer. 2020 Feb;11(2):295-304. doi: 10.1111/1759-7714.13256. Epub 2019 Dec 2.
5
LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.长链非编码 RNA PSMB8-AS1 通过调控 miR-382-3p/STAT1/PD-L1 轴促进胰腺癌进展。
J Exp Clin Cancer Res. 2020 Sep 5;39(1):179. doi: 10.1186/s13046-020-01687-8.
6
Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.长链非编码 RNA MALAT1 敲低通过调节 miR-200a-3p/FOXA1 抑制间变性甲状腺癌的进展。
Cancer Biol Ther. 2019;20(11):1355-1365. doi: 10.1080/15384047.2019.1617567. Epub 2019 Sep 10.
7
Long non-coding RNA MALAT1 regulates cardiomyocytes apoptosis after hypoxia/reperfusion injury via modulating miR-200a-3p/PDCD4 axis.长链非编码 RNA MALAT1 通过调节 miR-200a-3p/PDCD4 轴调控心肌细胞缺氧/再灌注损伤后的细胞凋亡。
Biomed Pharmacother. 2019 Mar;111:1036-1045. doi: 10.1016/j.biopha.2018.12.122. Epub 2019 Jan 11.
8
MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.miR-142-3p/MALAT1 通过抑制β-catenin 表达抑制肺癌进展。
Biomed Pharmacother. 2019 Jun;114:108847. doi: 10.1016/j.biopha.2019.108847. Epub 2019 Apr 7.
9
LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.长链非编码 RNA MALAT1 通过调控 miR-185-5p/MDM4 轴促进非小细胞肺癌进展。
Cancer Med. 2020 Dec;9(23):9138-9149. doi: 10.1002/cam4.3570. Epub 2020 Nov 4.
10
Long non-coding RNA PVT1 contributes to cell growth and metastasis in non-small-cell lung cancer by regulating miR-361-3p/SOX9 axis and activating Wnt/β-catenin signaling pathway.长链非编码 RNA PVT1 通过调控 miR-361-3p/SOX9 轴和激活 Wnt/β-catenin 信号通路促进非小细胞肺癌细胞的生长和转移。
Biomed Pharmacother. 2020 Jun;126:110100. doi: 10.1016/j.biopha.2020.110100. Epub 2020 Mar 24.

引用本文的文献

1
LncRNA SNHG15 targets miR-200a-3p affects the proliferation, apoptosis, migration, and invasion of cervical cancer cells.长链非编码RNA SNHG15靶向miR-200a-3p影响宫颈癌细胞的增殖、凋亡、迁移和侵袭。
BMC Cancer. 2025 Aug 7;25(1):1279. doi: 10.1186/s12885-025-14600-3.
2
PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.PD-L1在恶性肿瘤中的重要性:对PD-L1在恶性肿瘤中作用的全面见解,从分子机制到治疗机遇
Clin Exp Med. 2025 Apr 3;25(1):106. doi: 10.1007/s10238-025-01641-y.
3
Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy.

本文引用的文献

1
Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.晚期非小细胞肺癌住院患者与门诊患者:特征与结局
Cancer Treat Res Commun. 2019;19:100130. doi: 10.1016/j.ctarc.2019.100130. Epub 2019 Mar 23.
2
Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2.长链非编码 RNA MALAT1 通过增强 mTOR 介导的 TCF7L2 翻译来调节癌症葡萄糖代谢。
Cancer Res. 2019 May 15;79(10):2480-2493. doi: 10.1158/0008-5472.CAN-18-1432. Epub 2019 Mar 26.
3
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
竞争性内源性RNA(ceRNAs)与癌症治疗耐药性
Cancer Drug Resist. 2024 Sep 25;7:37. doi: 10.20517/cdr.2024.66. eCollection 2024.
4
To Elucidate the Effective Role of Small Molecule Regulated lncRNAs in the Tumour Microenvironment in Immunotherapy.阐明小分子调控的长链非编码RNA在免疫治疗中肿瘤微环境的有效作用。
Curr Med Chem. 2025;32(24):4947-4962. doi: 10.2174/0109298673318929240829065611.
5
Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis.外泌体作为肾细胞癌治疗、诊断和预后的新型工具。
Heliyon. 2024 Jun 13;10(12):e32875. doi: 10.1016/j.heliyon.2024.e32875. eCollection 2024 Jun 30.
6
miR-200a-3p promotes the malignancy of endometrial carcinoma through negative regulation of epithelial-mesenchymal transition.miR-200a-3p通过负向调控上皮-间质转化促进子宫内膜癌的恶性进展。
Discov Oncol. 2024 Jun 25;15(1):243. doi: 10.1007/s12672-024-01106-w.
7
Dysregulation of lncRNA MALAT1 Contributes to Lung Cancer in African Americans by Modulating the Tumor Immune Microenvironment.长链非编码RNA MALAT1的失调通过调节肿瘤免疫微环境导致非裔美国人患肺癌。
Cancers (Basel). 2024 May 15;16(10):1876. doi: 10.3390/cancers16101876.
8
Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance.长链非编码RNA MALAT-1:癌症进展、转移、免疫及治疗抗性中的多功能调节因子
Noncoding RNA Res. 2024 Feb 1;9(2):388-406. doi: 10.1016/j.ncrna.2024.01.015. eCollection 2024 Jun.
9
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.微小RNA作为癌症免疫治疗中免疫检查点的调节因子:靶向程序性死亡受体1/程序性死亡受体配体1和细胞毒性T淋巴细胞相关蛋白4通路
Cancer Cell Int. 2024 Mar 10;24(1):102. doi: 10.1186/s12935-024-03293-6.
10
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.从免疫检查点到治疗方法:了解免疫检查点调控以及天然产物和传统医学对肺癌免疫检查点和免疫治疗的影响。
Front Immunol. 2024 Feb 15;15:1340307. doi: 10.3389/fimmu.2024.1340307. eCollection 2024.
真实世界实践中抗 PD-1 治疗的非小细胞肺癌患者的特征和治疗结局的综合分析。
J Cancer Res Clin Oncol. 2019 Jun;145(6):1613-1623. doi: 10.1007/s00432-019-02899-y. Epub 2019 Mar 25.
4
Identification of prognostic biomarkers of prostate cancer with long non-coding RNA-mediated competitive endogenous RNA network.基于长链非编码RNA介导的竞争性内源性RNA网络鉴定前列腺癌的预后生物标志物
Exp Ther Med. 2019 Apr;17(4):3035-3040. doi: 10.3892/etm.2019.7277. Epub 2019 Feb 14.
5
Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.用纳米颗粒递送的小干扰 RNA 沉默 PD-1 和 PD-L1 可增加肿瘤浸润淋巴细胞的细胞毒性。
Nanomedicine (Lond). 2019 Apr;14(8):955-967. doi: 10.2217/nnm-2018-0237. Epub 2019 Mar 22.
6
Macrophages participate in the immunosuppression of condyloma acuminatum through the PD-1/PD-L1 signaling pathway.巨噬细胞通过 PD-1/PD-L1 信号通路参与尖锐湿疣的免疫抑制。
J Chin Med Assoc. 2019 May;82(5):413-418. doi: 10.1097/JCMA.0000000000000090.
7
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.PD-1 和 PD-L1 在癌症免疫治疗中的作用:临床意义和未来思考。
Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19.
8
Immunotherapy in endometrial cancer: new scenarios on the horizon.免疫疗法在子宫内膜癌中的应用:新的前景。
J Gynecol Oncol. 2019 May;30(3):e46. doi: 10.3802/jgo.2019.30.e46.
9
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?PD-L1 检测在非小细胞肺癌中的成本效益有哪些影响因素?
Lung Cancer. 2019 Jun;132:152-153. doi: 10.1016/j.lungcan.2019.03.011. Epub 2019 Mar 11.
10
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.同时阻断 CD47 和 PD-L1 可增强固有和适应性癌症免疫反应及细胞因子释放。
EBioMedicine. 2019 Apr;42:281-295. doi: 10.1016/j.ebiom.2019.03.018. Epub 2019 Mar 14.